多替阿巴拉米片阻断效果如何

(Simeika) was initially approved for marketing in the United States in 2014 and is currently the only three-in-one compound drug containing dolutegravir (DTG). Dolutegra abalamib tablets (Suimeike) have been approved for marketing in 50 countries and regions, and are recommended by many authoritative academic institutions and authoritative guidelines in Europe and the United States as the first-line first-line treatment for patients with HIV infection.

From a pharmacokinetic perspective, Domitabalamid Tablets (Simeika) can be taken with or without food. For adults or adolescents weighing more than 40 kg, the recommended dose of Domitabalamid tablets (Simeike) is one tablet, once daily. Adults or adolescents whose body weight is less than 40 kg should not be given Trimax because dolutea (Trimax) is a fixed-dose tablet and cannot be reduced.

If the patient misses a dose of Doptabalamid Tablets (Suimeike), and there are more than 4 hours before the next dose, he should take Doptabalamid Tablets (Suimeike) as soon as possible. If the next dose is less than 4 hours away, patients should not take the missed dose and simply resume their usual dosing schedule. 

How effective is the blocking effect of Dolutegra Abalamid Tablets?

Dolutegravir tablets (Simeike) are based on DTG (dolutegravir) integrase inhibitors. In clinical trials, DTG had a low discontinuation rate due to adverse drug reactions (ADR) or virological failure, which were 5.8% and 0.5% respectively. In the SINGLE trial, the 48-week primary analysis showed that the proportion of patients who achieved virological suppression was better in the dolutegravir XxXABC/3TC group than in the FTC/TDF/ETC group. It can be seen that doptabalamid tablets (Suimeike) have obvious viral suppression effect and low incidence of side effects, making it a good choice for HIV patients.

  The above is the introduction about (Sui Mei Kai). If patients have other questions about the drug (such as drug price, purchasing channels, etc.), they can consult the medical companion travel service.

Recommended related hot articles: /newsDetail/85405.html